Arthneeti
CR

Corona Remedies Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Corona Remedies Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,143
Market cap₹12.8K Cr
P/E60.6
Updated23 Aug 2026
Read4 min read

The short version

Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches. CORONA Remedies Limited targets a revenue growth of 15% organically and 25% from the acquired portfolio in FY27.

From Corona Remedies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches.
  • CORONA Remedies expects to outperform the market volume growth by about 3x to 4x through added medical representatives and restructuring of divisions, including launching new products like Wokadine.
  • Committed to 15% organic revenue growth domestically and 25% growth in the acquired portfolio, targeting 20%+ PAT growth in FY27.

2 more points management made on revenue & sales performance

Profitability & Margins

See what Corona Remedies Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Expansion of manufacturing capabilities with the addition of a new 600-kg production line.
  • Commissioning of a dedicated hormone manufacturing plant expected to be operational in Q1 or Q2 of FY27.
  • Receipt of EAEU GMP certification enabling expansion into key Eurasian markets (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan).
  • These investments aim to strengthen manufacturing backbone, improve scalability, and support growth in domestic and international business.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Corona Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript from CORONA Remedies Limited's earnings call does not provide specific details about the current or expected order book or pending orders. The discussion primarily revolves around revenue growth, market expansion (domestic and international), margin outlook, sales force productivity, and product launches. Key takeaways related to business outlook: - Anticipated overall IPM (Indian Pharma Market) growth of around 10% to 10.3% for FY '27. - Company targeting 15% organic revenue growth and 25% growth from acquired portfolios. - International business forecasted to grow at a high single-digit rate (~8-9%) over the next 3-4 years.

2 more points management made on order book & pipeline

Corona Remedies Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹353 Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Corona Remedies's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Aptus Pharma Ltd (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

  • Morepen Laboratories Ltd (Q4 FY26)

    472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…

  • Anuh Pharma Ltd (Q4 FY26)

    202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…

  • Themis Medicare Ltd (Q4 FY26)

    Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Corona Remedies Ltd Q4 FY26 results?

Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches. CORONA Remedies Limited targets a revenue growth of 15% organically and 25% from the acquired portfolio in FY27.

What is Corona Remedies Ltd share price analysis?

Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.

Is Corona Remedies Ltd planning capital expenditure?

Expansion of manufacturing capabilities with the addition of a new 600-kg production line.

Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.